In occasion of the 16th Meeting of the Committee on Bioethics (DH -BIO) held on 19-21 November 2019, the Strategic Action Plan on Human Rights and Technologies in Biomedicine has been adopted for the period 2020-2025. The vision and approach of the Strategic Action Plan are to protect human dignity and the human rights and
We are happy to announce that the article “Different Strategies to Execute Multi-Database Studies for Medicines Surveillance in Real-World Setting: A Reflection on the European Model” was published on Clinical Pharmacology & Therapeutics Journal. The publication derives from the activities carried out by the Working Group 3 ‘Data Sources and Multi-source Studies’ of the European
We are happy to present you the last novelty on TEDDY identity and governance. A new statute, indeed, has been approved by its associated members, foreseeing novelties in TEDDY identity and governance. The first news is related to the mission, oriented towards an integrated work with subjects involved in paediatric drugs development processes and aimed
We are happy to announce that TEDDY became a member of Enpr-EMA Coordinating Group. The European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) is a network of research networks, investigators and centres with recognised expertise in performing clinical studies in children. Enpr-EMA is governed by a coordinating group which sets the network's
The EPTRI Open Meeting on April 2-3 April 2020, due to Covid-19 outbreak, was run online. EPTRI is an EU funded project coordinated by CVBF and aimed to design the framework for a new infrastructure dedicated to paediatric research that will work to accelerate a technology-driven paediatric medicines development processes from drug discovery and early
In January 2019, the European Joint Programme on Rare Diseases (EJPRD) started its activities aimed to create a comprehensive, sustainable system allowing virtuous circle between research, care and medical innovation. TEDDY Network is among the beneficiaries of this new Co-fund action and provides its contribution in this programme intended to create a research and innovation
On 26 March 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Nepexto (etanercept), intended for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis, non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.
On 26 March 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Ruconest (conestat alfa). The marketing authorisation holder for this medicinal product is Pharming Group N.V. The Committee for Medicinal Products for Human Use (CHMP)
The 10th European Conference on Rare Diseases & Orphan Products (ECRD) will take place ONLINE on 14-15 May The ECRD is recognised globally as the largest, patient-led rare disease event in which collaborative dialogue, learning and conversation takes place, forming the groundwork to shape future rare diseases policies. Leading, inspiring and engaging all stakeholders to
A pneumonia of unknown cause detected in Wuhan, China was first reported to the World Health Organisation Country Office in China on 31 December 2019. After just three months WHO characterised COVID-19 as pandemic, currently affecting 157 countries and territories around the world. Besides the impact on international financial market and individual social life, COVID-19